Chutian Technology's 2021 semi-annual report was released on August 27. Many indicators such as revenue and net profit have risen sharply. In the first half of the year, operating income was 2.391 billion yuan, a year-on-year increase of 72.75%; net profit attributable to shareholders of listed companies was 236 million Yuan, a year-on-year increase of 1321.22%. Among the many product sectors that support business performance, inspection and packaging solutions and stand-alone business are very eye-catching, with revenue reaching 830 million yuan, an increase of 135.42% year-on-year, while the bioengineering solutions and stand-alone business sectors are developing rapidly, with revenue increasing year-on-year 255.41%. R&D investment continued to rise steadily, reaching nearly 200 million yuan, a year-on-year increase of 65.65%. Although overseas markets are affected by the uncertainty of the new crown epidemic, Chutian Technology has also performed well in several overseas regions in the first half of 2021. For example, revenue in Europe increased by 11.27% and revenue in America increased by 74.67%.

The substantial increase in Chutian Technology's operating performance stems from the active implementation and promotion of the strategy. The company has continuously improved its market and marketing capabilities, strengthened its internal operation and management capabilities, and fully utilized the synergies of its subsidiaries. In the first half of 2021, new orders increased by 136% year-on-year. On this basis, Chutian Technology has continuously improved its product manufacturing, delivery and debugging capabilities, and product delivery has increased significantly over the same period of the previous year. Continuously increasing R&D investment in new technologies and new products is also an important driving force for performance growth. Chutian Technology's product structure and configuration have been continuously optimized, and product technology and product quality have continued to improve. At the same time, Chutian Technology has also achieved important results in internal cost control and supply chain optimization.

Driven by the two-wheel drive of intensive growth and extensional development, Chutian Technology is currently the only company in the industry that has the ability to supply both aquatic solution and solid preparation solutions, and has many highly competitive product portfolios. Product upgrades and new product development have also continued to yield results. The rapid growth of Chutian Technology's bioengineering business in the first half of the year is one of the results. At present, Chutian Technology has formed stainless steel reaction fermentation system, chromatographic separation and purification system, liquid preparation system and other related programs and products in the front stage of biology, and has completed the layout of some key customers. Layout and development of related consumables to continuously improve the product chain.

The development of product layout and the increase in R&D investment have also brought about the expansion of the scale of R&D personnel. Chutian Technology has exceeded 1,500 R&D personnel in the first half of 2021. Chutian Technology adheres to the "dual priority" strategy of product technology and manufacturing technology, and its manufacturing and processing capabilities have been continuously improved, especially the steadily improved processing technology and level of core components, which further promoted the improvement of product quality. Its subsidiary Chutian Huaxing has continued to scale Its good precision manufacturing capabilities have undertaken important processing tasks for Chutian Technology. The integration of the Romaco Group’s German manufacturing concept is also continuing to improve the manufacturing level of Chutian Technology. With the steady progress of the fourth phase of the project, the company’s production capacity It is also constantly improving.

While Chutian Technology's business performance is growing well, it is also actively fulfilling its social responsibilities, especially playing an indispensable force in the fight against the new crown epidemic. In response to the country’s call to increase the scale of the new crown vaccine production and guarantee the supply of the new crown vaccine, Chutian Technology has efficiently mobilized the company’s technical R&D, manufacturing, and after-sales service forces to develop a washing-baking-filling-sealing linkage production line, intelligent testing equipment, The core equipment for large-scale production of the new crown vaccine such as the post-packaging production line fully guarantees the production of China's important new crown vaccine companies such as China National Pharmaceutical Group, Kexing, Kangsino, and Zhifeilong Kema, and has made important contributions to the supply of China's new crown vaccine.